Jean Bennett

Author PubWeight™ 130.65‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008 17.21
2 Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009 6.71
3 Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 2005 4.74
4 Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success. Proc Natl Acad Sci U S A 2005 4.04
5 Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2009 3.93
6 Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther 2008 3.28
7 Impairment of the transient pupillary light reflex in Rpe65(-/-) mice and humans with leber congenital amaurosis. Invest Ophthalmol Vis Sci 2004 2.72
8 Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003 2.68
9 In utero gene therapy rescues vision in a murine model of congenital blindness. Mol Ther 2004 2.56
10 Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Invest 2008 2.40
11 Mutations in ABCA4 result in accumulation of lipofuscin before slowing of the retinoid cycle: a reappraisal of the human disease sequence. Hum Mol Genet 2004 2.30
12 Lateral connectivity and contextual interactions in macaque primary visual cortex. Neuron 2002 2.16
13 Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol Ther 2006 2.13
14 Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies. J Clin Invest 2010 2.13
15 Eye movement recordings as an effectiveness indicator of gene therapy in RPE65-deficient canines: implications for the ocular motor system. Invest Ophthalmol Vis Sci 2006 2.01
16 Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology 2013 1.85
17 Novel AAV serotypes for improved ocular gene transfer. J Gene Med 2008 1.80
18 Gene therapy for choroideremia: in vitro rescue mediated by recombinant adenovirus. Vision Res 2003 1.63
19 AAV-mediated gene therapy for choroideremia: preclinical studies in personalized models. PLoS One 2013 1.62
20 Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011 1.54
21 Light damage induced changes in mouse retinal gene expression. Exp Eye Res 2004 1.54
22 The human visual cortex responds to gene therapy-mediated recovery of retinal function. J Clin Invest 2011 1.52
23 Mutations in RPGR and RP2 account for 15% of males with simplex retinal degenerative disease. Invest Ophthalmol Vis Sci 2012 1.47
24 Retinal ganglion cell loss induced by acute optic neuritis in a relapsing model of multiple sclerosis. Mult Scler 2006 1.44
25 ABCA4-associated retinal degenerations spare structure and function of the human parapapillary retina. Invest Ophthalmol Vis Sci 2005 1.40
26 Systemic but not intraocular Epo gene transfer protects the retina from light-and genetic-induced degeneration. Mol Ther 2004 1.35
27 Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness. Sci Transl Med 2010 1.35
28 Disruption of intraflagellar protein transport in photoreceptor cilia causes Leber congenital amaurosis in humans and mice. J Clin Invest 2011 1.31
29 Herpes simplex virus type 1 glycoprotein e is required for axonal localization of capsid, tegument, and membrane glycoproteins. J Virol 2005 1.29
30 Tie2Cre-mediated inactivation of plexinD1 results in congenital heart, vascular and skeletal defects. Dev Biol 2008 1.29
31 Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 2004 1.27
32 Progress in gene therapy for neurological disorders. Nat Rev Neurol 2013 1.22
33 Dissecting the axoneme interactome: the mammalian orthologue of Chlamydomonas PF6 interacts with sperm-associated antigen 6, the mammalian orthologue of Chlamydomonas PF16. Mol Cell Proteomics 2005 1.21
34 Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa. Mol Ther 2011 1.16
35 In vivo delivery of recombinant viruses to the fetal murine cochlea: transduction characteristics and long-term effects on auditory function. Mol Ther 2006 1.15
36 Deficiency of SPAG16L causes male infertility associated with impaired sperm motility. Biol Reprod 2005 1.14
37 Oxygen distribution and vascular injury in the mouse eye measured by phosphorescence-lifetime imaging. Appl Opt 2005 1.13
38 Increased expression of ceruloplasmin in the retina following photic injury. Mol Vis 2003 1.13
39 Long-term inducible gene expression in the eye via adeno-associated virus gene transfer in nonhuman primates. Hum Gene Ther 2005 1.07
40 Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye. Mol Ther 2002 1.07
41 Accelerated mortality from hydrocephalus and pneumonia in mice with a combined deficiency of SPAG6 and SPAG16L reveals a functional interrelationship between the two central apparatus proteins. Cell Motil Cytoskeleton 2007 1.07
42 Disease expression in Usher syndrome caused by VLGR1 gene mutation (USH2C) and comparison with USH2A phenotype. Invest Ophthalmol Vis Sci 2005 1.06
43 Antisense Oligonucleotide (AON)-based Therapy for Leber Congenital Amaurosis Caused by a Frequent Mutation in CEP290. Mol Ther Nucleic Acids 2012 1.05
44 Persistent fetal ocular vasculature in mice deficient in bax and bak. Arch Ophthalmol 2005 1.04
45 Nonhuman primate models for diabetic ocular neovascularization using AAV2-mediated overexpression of vascular endothelial growth factor. Diabetes 2005 1.04
46 A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virus. Mol Ther 2002 1.04
47 Delivery of adeno-associated virus vectors to the fetal retina: impact of viral capsid proteins on retinal neuronal progenitor transduction. J Virol 2003 1.02
48 Gene transfer to ocular stem cells by early gestational intraamniotic injection of lentiviral vector. Mol Ther 2007 1.02
49 Disruption of CEP290 microtubule/membrane-binding domains causes retinal degeneration. J Clin Invest 2013 1.01
50 AAV9 targets cone photoreceptors in the nonhuman primate retina. PLoS One 2013 1.00
51 Macular pigment and lutein supplementation in choroideremia. Exp Eye Res 2002 0.98
52 Pupillometric analysis for assessment of gene therapy in Leber Congenital Amaurosis patients. Biomed Eng Online 2012 0.98
53 Novel mutation in the TIMP3 gene causes Sorsby fundus dystrophy. Arch Ophthalmol 2002 0.95
54 Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther 2002 0.94
55 Proapoptotic bcl-2 family members, Bax and Bak, are essential for developmental photoreceptor apoptosis. Invest Ophthalmol Vis Sci 2003 0.92
56 The distribution, concentration, and toxicity of enhanced green fluorescent protein in retinal cells after genomic or somatic (virus-mediated) gene transfer. Mol Vis 2005 0.91
57 Adeno-associated virus mediated gene therapy for retinal degenerative diseases. Methods Mol Biol 2011 0.90
58 Immunology of AAV-Mediated Gene Transfer in the Eye. Front Immunol 2013 0.90
59 Imaging oxygen pressure in the retina of the mouse eye. Adv Exp Med Biol 2005 0.86
60 Gene therapy and animal models for retinal disease. Dev Ophthalmol 2003 0.85
61 CEP290 and the primary cilium. Adv Exp Med Biol 2014 0.84
62 Gene therapy in ophthalmology: validation on cultured retinal cells and explants from postmortem human eyes. Hum Gene Ther 2011 0.84
63 Gene therapy for ocular neovascularization: a cure in sight. Curr Opin Genet Dev 2003 0.83
64 Using the NAFX to measure the effectiveness over time of gene therapy in canine LCA. Invest Ophthalmol Vis Sci 2009 0.83
65 Phenotypic rescue after adeno-associated virus-mediated delivery of 4-sulfatase to the retinal pigment epithelium of feline mucopolysaccharidosis VI. J Gene Med 2002 0.83
66 Seeing the light. Sci Transl Med 2013 0.82
67 Adeno-associated virus 8-mediated gene therapy for choroideremia: preclinical studies in in vitro and in vivo models. J Gene Med 2014 0.82
68 Adeno-associated viruses containing bFGF or BDNF are neuroprotective against excitotoxicity. Curr Eye Res 2004 0.81
69 Dark-rearing the rd10 mouse: implications for therapy. Adv Exp Med Biol 2012 0.81
70 Effect of over-expression of pigment epithelium derived factor (PEDF) on developing retinal vasculature in the mouse. Mol Vis 2004 0.79
71 Adeno-Associated Virus-Mediated Gene Transfer to Renal Tubule Cells via a Retrograde Ureteral Approach. Nephron Extra 2011 0.78
72 Spatial and temporal expression patterns of the choroideremia gene in the mouse retina. Mol Vis 2005 0.78
73 Imaging oxygen pressure in the rodent retina by phosphorescence lifetime. Adv Exp Med Biol 2006 0.77
74 Gene therapy for Leber congenital amaurosis. Adv Exp Med Biol 2003 0.77
75 Switching on the lights: the use of optogenetics to advance retinal gene therapy. Mol Ther 2011 0.77
76 The Signalling Role of the avβ5-Integrin Can Impact the Efficacy of AAV in Retinal Gene Therapy. Pharmaceuticals (Basel) 2012 0.77
77 Nxnl2 splicing results in dual functions in neuronal cell survival and maintenance of cell integrity. Hum Mol Genet 2012 0.76
78 Exploiting metabolic and antioxidant pathways to maintain vision in blinding disease. J Clin Invest 2015 0.76
79 Adeno-associated virus encoding green fluorescent protein as a label for retinal pigment epithelium. Invest Ophthalmol Vis Sci 2003 0.76
80 Stem cells set their sights on retinitis pigmentosa. Elife 2013 0.75
81 Correction: AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models. PLoS One 2015 0.75
82 The bionic retina: a small molecule with big potential for visual restoration. Neuron 2012 0.75
83 Promising first steps in gene therapy for choroideremia. Hum Gene Ther 2014 0.75
84 Novel mathematical algorithm for pupillometric data analysis. Comput Methods Programs Biomed 2013 0.75
85 Corrigendum to "Efficient gene delivery to photoreceptors using AAV2/rh10 and rescue of the Rho-/- mouse". Mol Ther Methods Clin Dev 2016 0.75
86 Müller cell transduction by AAV2 in normal and degenerative retinas. Adv Exp Med Biol 2003 0.75